Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs
JSR Life Sciences, LLC (JSR) and Blau Farmaceutica (Blau) (public company in Brazil B3 BLAU3) today announced that Similis Bio (Similis), its recently launched business unit focused on biosimilar development, has signed its first development and license agreement with Blau Farmacutica (Blau).
- JSR Life Sciences, LLC (JSR) and Blau Farmaceutica (Blau) (public company in Brazil B3 BLAU3) today announced that Similis Bio (Similis), its recently launched business unit focused on biosimilar development, has signed its first development and license agreement with Blau Farmacutica (Blau).
- We are thrilled to partner with Blau as they work to launch their biosimilar business initially in North and South America.
- Similis Bio will provide full processes and associated IP for tech transfer to Blau, including cell lines, analytical data and methodologies, and upstream/downstream processes.
- JSR launched Similis Bio to mitigate the innate barriers to market entry for biosimilars and promote more productive development programs.